Neuro-oncology
Conference Coverage
Chemotherapy-induced peripheral neuropathy tied to compromised executive function
Chemotherapy-related mobility declines in CIPN survivors are likely due to both neuromuscular and executive dysfunction.
Hitting a Nerve
Babe Ruth’s unique cane, and why he used it
Seventy-five years after his death, the case of Babe Ruth still presents pertinent questions.
From the Journals
Can a biodegradable brain implant deliver lifesaving cancer meds?
The tumors shrank, and the mice doubled their lifetime, compared with untreated mice.
Conference Coverage
Oral drug for brain tumor could change treatment landscape
Vorasidenib was associated with a significant delay in time to disease progression when compared with placebo, in a new study.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
From the Journals
Plasma monitoring supports earlier osimertinib treatment in lung cancer patients
More patients met progression-free survival endpoints after shorter stint on gefitinib.
Conference Coverage
Study gives new insight into timing of combo treatment in metastatic NSCLC
Best outcomes came when immunotherapy followed radiotherapy by 1-12 months.
Conference Coverage
First target doesn’t affect survival in NSCLC with brain metastases
Patient outcomes didn’t hinge on whether oncologists treated the brain or lung first.
Latest News
A single pediatric CT scan raises brain cancer risk
"CT examinations should only be used when necessary, and if they are used, the lowest achievable dose should be applied."
Literature Review
High drug costs exclude most neurology patients from cutting-edge treatment
“Our study of people with neurologic conditions found that fewer than 20% were being treated with new medications.”
Feature
Glioblastoma spreading strategies discovered
The more-or-less specific interaction between the nerve cells and the tumor cells also offers starting points for therapies, from our point of...